Characteristic | Second patient cohort (n = 60) | |
---|---|---|
Pretreatment (n = 30) | Posttreatment (n = 30) | |
Age, years | 56 (37–64) |  |
Female, n (%) | 26 (88) | Â |
Disease duration, months | 13 (3–47) |  |
Stage I/II/III/IV, n | 14/14/0/2 | Â |
Class 1/2/3/4, n | 9/19/2/0 | Â |
RF-positive, n (%) | 22 (73) | Â |
ACPA-positive, n (%) | 22 (73) | Â |
Methotrexate use, n (%) | 18 (60) | 28 (93) |
Biologic use, n (%) | 5 (17) | 21 (70) |
DAS28-ESR | 4.8 (3.7–6.4) | 2.0 (1.0–2.8) |
DAS28-CRP | 4.0 (3.2–5.5) | 1.5 (1.1–2.3) |
SDAI | 16.0 (11.5–32.9) | 1.8 (0.3–5.4) |
CDAI | 15.4 (10.8–31.2) | 1.8 (0.3–5.4) |
SJC, 28 joints, n | 4 (3–8.5) | 0 (0–1) |
TJC, 28 joints, n | 6 (3–10) | 0 (0–1) |
PtGA, mm | 48 (27–73) | 35 (11–53) |
PGA, mm | 31 (20–52) | 2 (0–11) |
CRP, mg/dl | 0.5 (0.1–1.2) | 0.0 (0.0–0.1) |
ESR, mm/h | 47 (28–67) | 8 (3–24) |
MMP-3, ng/ml | 79 (49–107) | 39 (24–53) |
HAQ-DI | 0.9 (0.3–1.4) | 0.1 (0–0.4) |